hsa-miR-150-5p miREIA
MicroRNAs (miRNAs) are small non-coding RNA molecules, approximately 22 nucleotides in length that regulate gene translation through silencing or degradation of target mRNAs. They are involved in multiple biological processes, including differentiation and proliferation, metabolism, hemostasis, apoptosis or inflammation, and in the pathophysiology of many diseases. Numerous studies have suggested circulating miRNAs as promising diagnostic and prognostic biomarkers of many diseases.
hsa-miR-150 is encoded by the gene located on the human chromosome 19q13. hsa-miR-150 is selectively expressed in lymph nodes, spleen, and in mature B- and T-cells, and is an important regulator of differentiation and activation of immune cells. It is also involved in the innate and adaptive immune responses. hsa-miR-150 is one of the most studied miRNA and plays an important role in pathogenesis of a number of tumours.
Low levels of hsa-miR-150 in pacient’s tumor samples predicted shorter survival and worse response to adjuvant chemotherapy; in contrast, high expression of hsa-miR-150 in pacient’s tumor samples indicates better prognosis and better response to adjuvant chemotherapy.
Moreover, over-expression of hsa-miR-150-5p leads to reduced migration and invasion of colorectal carcinoma cells. hsa-miR-150-5p also acts as a metastasis suppressor in colorectal carcinoma.
Plasma levels of hsa-miR-150 were downregulated in patients with acute myeloid leukemia.
hsa-miR-150-5p was upregulated in tumor tissues of non-small-cell lung carcinoma (NSLC) patients and was negatively correlated with expression of the tumor-suppressor geneTP53.
High levels of hsa-miR-150 were observed in gastric cancer tissue. hsa-miR-150 over-expression also promoted gastric cancer proliferation. Furthermore, over-expression of hsa-miR-150 was found in osteosarcoma tumor samples.
Type
miREIA – miRNA enzyme immunoassay
Applications
Whole blood, PBMC
Sample Requirements
10 µl/well
Storage/Expiration
Store the complete kit at 2 – 8 °C. Under these conditions, all components are stable until the expiration date (see label on the box).
Calibration Curve
Calibration Range
12.5 – 0.39 amol/μl
Limit of Detection
0.13 amol/μl
Intra-assay (Within-Run)
n = 8,
CV = 4.9%
Inter-assay (Run-to-Run)
n = 5,
CV = 9.7%
Spiking Recovery
103.5%
Dilutation Linearity
95.9%
- XIA, Bairong, et al. Long non-coding RNA ZFAS1 interacts with miR-150-5p to regulate Sp1 expression and ovarian cancer cell malignancy. Oncotarget, 2017, 8.12: 19534.
- SANG, Wei, et al. MiR-150 impairs inflammatory cytokine production by targeting ARRB-2 after blocking CD28/B7 costimulatory pathway. Immunology letters, 2016, 172: 1-10.
- LIN, You-Chin, et al. c-Myb is an evolutionary conserved miR-150 target and miR-150/c-Myb interaction is important for embryonic development. Molecular biology and evolution, 2008, 25.10: 2189-2198.
- ZHOU, Beiyan, et al. miR-150, a microRNA expressed in mature B and T cells, blocks early B cell development when expressed prematurely. Proceedings of the National Academy of Sciences, 2007, 104.17: 7080-7085.
- WANG, Wei-Hua, et al. MiR-150-5p suppresses colorectal cancer cell migration and invasion through targeting MUC4. Asian Pac J Cancer Prev, 2014, 15.15: 6269-73.
- MA, Yanlei, et al. miR-150 as a potential biomarker associated with prognosis and therapeutic outcome in colorectal cancer. Gut, 2012, 61.10: 1447-1453.
- FAYYAD-KAZAN, Hussein, et al. Circulating miR-150 and miR-342 in plasma are novel potential biomarkers for acute myeloid leukemia. Journal of translational medicine, 2013, 11.1: 31.
- ZHANG, Ni; WEI, Xiang; XU, Lijun. miR‐150 promotes the proliferation of lung cancer cells by targeting P53. FEBS letters, 2013, 587.15: 2346-2351.
- LULLA, Rishi R., et al. Identification of differentially expressed microRNAs in osteosarcoma. Sarcoma, 2011, 2011.